Siirry päänavigointiin
Siirry hakuun
Siirry pääsisältöön
Järjestys:
Medicine and Dentistry
Radiation Therapy
100%
Breast Cancer
99%
Prostate Cancer
54%
Quality of Life
37%
Cancer Radiotherapy
30%
Adjuvant Radiotherapy
27%
Overall Survival
23%
Image-Guided Intervention
22%
Biological Marker
21%
Vertebra
19%
Aromatase Inhibitor
18%
Malignant Neoplasm
18%
Symptomatic Treatment
16%
Cancer
16%
Tumor
15%
Adjuvant Chemotherapy
15%
Castration Resistant Prostate Cancer
15%
CA19-9
15%
Carcinoembryonic Antigen
15%
Head and Neck Cancer
15%
Colorectal Carcinoma
15%
Interleukin 6
15%
Docetaxel
15%
External Beam Radiotherapy
15%
Diastolic Function
15%
Thyroid Cancer
15%
Lymph Node
15%
Chemotherapy
14%
Hazard Ratio
14%
Echocardiography
13%
Decision Making
12%
Clear Cell Renal Cell Carcinoma
12%
Systolic Function
11%
Arm
10%
Troponin T
10%
Cancer Therapy
10%
Breast Radiotherapy
10%
Diseases
9%
Health Care Cost
9%
Androgen Receptor
9%
Comorbidity
9%
Neoplasm
8%
Long Term Survival
8%
Thoracic Wall
8%
Papillary Thyroid Cancer
8%
Sternum
8%
Disease Free Survival
7%
Physical Activity
7%
Bone Density
7%
Diffuse Large B-Cell Lymphoma
7%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
76%
Docetaxel
42%
Prostate Cancer
36%
Chemotherapy Regimens
30%
Castration Resistant Prostate Cancer
30%
Paclitaxel
22%
Malignant Neoplasm
21%
Overall Survival
19%
Adverse Event
17%
Capecitabine
15%
Trastuzumab
15%
Ifosfamide
15%
Neutropenia
13%
Diseases
13%
Disease Free Survival
10%
Metastatic Breast Cancer
9%
Endocrine Therapy
9%
Androgen Receptor
9%
Anthracycline
8%
Vinorelbine
8%
Prostate Specific Antigen
8%
Epirubicin
8%
Cyclophosphamide
8%
Side Effect
8%
Fluorouracil
7%
Carcinoembryonic Antigen
7%
Toremifene
7%
Aromatase Inhibitor
7%
Interleukin 6
7%
Bevacizumab
7%
Vasculotropin Receptor 1
7%
Vasculotropin Receptor 2
7%
Metastatic Melanoma
7%
Disease Specific Survival
7%
Thyroid Cancer
7%
Thyroid Papillary Carcinoma
7%
Abemaciclib
7%
Cabazitaxel
7%
Randomized Clinical Trial
7%
Colorectal Carcinoma
7%
Brain Metastasis
7%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
7%
Lapatinib
7%
Afatinib
7%
Infection
6%
Tolerability
5%
Disease Exacerbation
5%
Tamoxifen
5%
Clinical Trial
5%
Keyphrases
Health-related Quality of Life
44%
Radiotherapy
31%
Early Breast Cancer
25%
Docetaxel
21%
Overall Survival
21%
Quality of Life
18%
Aggressive Prostate Cancer
17%
Cancer Patients
16%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
15%
Early Breast Cancer Patients
15%
Advanced Breast Cancer
15%
External Beam Radiotherapy
15%
Palliative Radiotherapy
15%
In Cancer
15%
Adjuvant Docetaxel
15%
Prostate Cancer
13%
Distant Disease-free Survival
13%
Prognostic Factors
11%
Adjuvant Chemotherapy
11%
Tumor
10%
Fractionation Schedules
10%
Finland
10%
Paclitaxel
10%
Randomized Trial
9%
Comorbidity
9%
15D Instrument
9%
Anemia
9%
Prostate Cancer Patients
9%
Chemotherapy
8%
Hazard Ratio
8%
Breast Cancer Survivors
8%
Intermediate Risk
8%
3-year Follow-up
8%
Anthracyclines
8%
Renal Cancer
7%
Cardiac Changes
7%
Cyclophosphamide
7%
Epirubicin
7%
Radiation Dose
7%
Systemic Therapy
7%
Claudin
7%
Circulating Levels
7%
Right Ventricular Systolic Function
7%
Right Ventricular Diastolic Dysfunction
7%
Right Ventricular
7%
Tricuspid Annular Plane Systolic Excursion (TAPSE)
7%
Early Effect
7%
Adjuvant Breast Cancer
7%
Right Ventricular Function
7%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer (HER2-positive breast cancer)
7%
